BliNK Therapeutics Ltd.

BliNK Therapeutics is a spin-out from Cancer Research Technology, the commercial arm of Cancer Research, UK, with financial support from Paris based Kurma Life Sciences Partners, to generate monoclonal antibodies.

BliNK Therapeutics Ltds technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at London Research Institute, Cancer Research UK.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.blinktherapeutics.com
Disease Focus
STOCK CODENon Listed
Address
Mercury House19-21 Chapel Street, SL7 3HN
Marlow
United Kingdom
Email
Contact Number

BliNK Therapeutics is a spin-out from Cancer Research Technology, the commercial arm of Cancer Research, UK, with financial support from Paris based Kurma Life Sciences Partners, to generate monoclonal antibodies.

BliNK Therapeutics Ltds technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at London Research Institute, Cancer Research UK.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/blink-therapeutics” connections=”true” suffix=””]

BliNK Therapeutics technology provides a new way of activating the immune systems B cells to produce antibodies in response to a specific antigen even when the Çparent B cells are rare or when the antigens are hard for B cells to detect.

In Dec 2014, Valneva SE and BliNK Therapeutics Ltd created a new private company BliNK Biomedical SAS with headquarter at Lyon, France to combine both companies validated antibody discovery platforms to develop proprietary human antibodies targeting immuno-oncology and oncology up to clinical stages.